Drug · CHEMBL71
CHLORPROMAZINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. CHLORPROMAZINE. Drugs and targets, record CHEMBL71. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL71
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- Aminazine, Chlorpromazinum, Clorpromazina, Esmind, Fenactil, J2.794D, Largactilothiazine, NSC-167745, NSC-226514, Novomazina, Propaphenin, SKF-2601A, Sanopron, Wintermin
- ChEMBL
- Open Targets' highest stage
- Approval, for 6 of its 15 diseases, from ATC, DailyMed and TTD
- Open Targets
Targets4
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| DRD2 | D2-like dopamine receptor | D2-like dopamine receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/1813 |
| DRD3 | D2-like dopamine receptor | D2-like dopamine receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/1814 |
| DRD4 | D2-like dopamine receptor | D2-like dopamine receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/1815 |
| HTR2A | 5-hydroxytryptamine receptor 2A | Serotonin 2a (5-HT2a) receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/3356 |
Source ChEMBL
Diseases15
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 15Source Open Targets
See all 15 diseasesTrials20
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT03639558 | TREC-Lebanon: A Trial for Rapid Tranquilisation for Agitated Patients in the Emergency Setting | Phase 4 | 100 | 2022-06-14 | chlorpromazine | Its name | ClinicalTrials.gov |
| NCT03021486 | Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer | Phase 2/3 | 70 | 2022-09-01 | chlorpromazine | Its name | ClinicalTrials.gov |
| NCT00654576 | Effectiveness of Antipsychotic Combination With Psychosocial Intervention on Outcome of Patients With Schizophrenia | Phase 4 | 1,400 | chlorpromazine | Its name | ClinicalTrials.gov | |
| NCT07152184 | Study Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Patients With Schizophrenia Spectrum Disorder: a Personalized Medicine Approach | Phase 2 | 288 | chlorpromazine | Its name | ClinicalTrials.gov | |
| NCT02810782 | How to Treat Opiate Withdrawal in Neonates | Phase 3 | 120 | chlorpromazine | Its name | ClinicalTrials.gov | |
| NCT04354805 | Administration of Chlorpromazine as a Treatment for COVID-19 | Phase 2/3 | 100 | chlorpromazine | Its name | ClinicalTrials.gov | |
| NCT00202293 | Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features | Phase 4 | 83 | chlorpromazine | Its name | ClinicalTrials.gov | |
| NCT00169039 | Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia | Phase 4 | 66 | chlorpromazine | Its name | ClinicalTrials.gov | |
| NCT07364344 | Safety and Preliminary Efficacy of Hibernation-Like Therapy (Chlorpromazine and Promethazine) in Patients With Acute Ischemic Stroke (AIS) Eligible for Reperfusion Therapy. | 57 | chlorpromazine | Its name | ClinicalTrials.gov | ||
| NCT05431595 | Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy | Phase 2/3 | 42 | chlorpromazine | Its name | ClinicalTrials.gov |
1 to 10 of 20
See all 20 trialsComparisons in its trials3
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Haloperidol + Promethazine + Chlorpromazine vs Haloperidol + Promethazine: Time Noted Where Important Adverse Effects Occurred Post Intervention | 0 of 52 | 0 of 48 | 100 | NCT03639558 | Trial comparisons |
| Haloperidol + Promethazine + Chlorpromazine vs Haloperidol + Promethazine: deaths from any cause | 0 of 52 | 0 of 48 | 100 | NCT03639558 | Trial comparisons |
| Haloperidol + Promethazine + Chlorpromazine vs Haloperidol + Promethazine: serious adverse events | 0 of 52 | 0 of 48 | 100 | NCT03639558 | Trial comparisons |
Papers from its trials20
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL71
GET https://conductscience.org/api/drugs/v1/CHEMBL71/targets